Page 3 - Tolerability Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program offers researchers a sm

“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.

“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.

BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease 8th April 2021 (Last Updated April 8th, 2021 18:15) BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada. The trial plans to enrol ten patients in the US and Canada. Credit: National Institute on Aging, National Institutes of Health. Share Article BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’...

BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease News provided by Share this article Share this article CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease (PD)." This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinso...